Warren D. Marcus

Immunology and Microbiology · Life Sciences

14h-index1.5kcitations30works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Immune Cell Function and Interaction(16), CAR-T cell therapy research(8), Monoclonal and Polyclonal Antibodies Research(6), Toxin Mechanisms and Immunotoxins(6), Cancer Immunotherapy and Biomarkers(4)

Publications30 total

Supplementary Figures 1 - 4 from Efficacy and Mechanism-of-Action of a Novel Superagonist Interleukin-15: Interleukin-15 Receptor αSu/Fc Fusion Complex in Syngeneic Murine Models of Multiple Myeloma
2023Open Access
Data from Efficacy and Mechanism-of-Action of a Novel Superagonist Interleukin-15: Interleukin-15 Receptor αSu/Fc Fusion Complex in Syngeneic Murine Models of Multiple Myeloma
2023Open Access
Data from Efficacy and Mechanism-of-Action of a Novel Superagonist Interleukin-15: Interleukin-15 Receptor αSu/Fc Fusion Complex in Syngeneic Murine Models of Multiple Myeloma
2023Open Access
Supplementary Figures 1 - 4 from Efficacy and Mechanism-of-Action of a Novel Superagonist Interleukin-15: Interleukin-15 Receptor αSu/Fc Fusion Complex in Syngeneic Murine Models of Multiple Myeloma
2023Open Access
The multi-functionality of N-809, a novel fusion protein encompassing anti-PD-L1 and the IL-15 superagonist fusion complex
OncoImmunology·2018· 41 citedOpen Access
Novel antibody-like single-chain TCR antibody Fc fusion protein
The Journal of Immunology·2017
Tissue factor-specific ultra-bright SERRS nanostars for Raman detection of pulmonary micrometastases
Nanoscale·2016· 49 citedOpen Access
A Novel Fusion of ALT-803 (Interleukin (IL)-15 Superagonist) with an Antibody Demonstrates Antigen-specific Antitumor Responses
Journal of Biological Chemistry·2016· 77 citedOpen Access
Therapeutic administration of IL-15 superagonist complex ALT-803 leads to long-term survival and durable antitumor immune response in a murine glioblastoma model
International Journal of Cancer·2015· 102 citedOpen Access
Enhanced efficacy of ALT-803, an IL-15-based superagonist complex, in combination with immune checkpoint inhibitors in an orthotopic muscle invasive bladder tumor model in mice
Journal for ImmunoTherapy of Cancer·2015Open Access
Enhanced efficacy of IL-15-based ALT-803 superagonist complex in combination with immune checkpoint inhibitors in hematologic and metastatic mouse tumor models
Journal for ImmunoTherapy of Cancer·2014Open Access
Evaluation of a novel CD20-targeted IL-15 immunotherapeutic with potent activity against B cell lymphoma
Journal for ImmunoTherapy of Cancer·2014· 4 citedOpen Access
Combinatorial therapy with an IL-15 superagonist (ALT-803) and anti-PD-L1 mAb augment T cell mediated anti-tumor immunity in mice
Journal for ImmunoTherapy of Cancer·2014Open Access
Novel antitumor mechanism-of-action of an IL-2 fusion protein mediated by tumor associated macrophage repolarization and innate-like CD8+ memory T cells
Journal for ImmunoTherapy of Cancer·2014· 1 citedOpen Access
Efficacy and Mechanism-of-Action of a Novel Superagonist Interleukin-15: Interleukin-15 Receptor αSu/Fc Fusion Complex in Syngeneic Murine Models of Multiple Myeloma
Cancer Research·2013· 190 citedOpen Access
Efficacy and mechanism-of-action of a novel superagonist IL-15:IL-15Rα/Fc fusion complex in murine multiple myeloma syngeneic mouse models (46.44)
The Journal of Immunology·2012
Efficacy and mechanism-of-action of a novel superagonist IL-15:IL-15R{alpha}/Fc fusion complex in murine multiple myeloma syngeneic mouse models
The Journal of Immunology·2012
IL-15:IL-15 receptor alpha superagonist complex: High-level co-expression in recombinant mammalian cells, purification and characterization
Cytokine·2011· 216 citedOpen Access
Novel Human Interleukin-15 Agonists
The Journal of Immunology·2009· 151 citedOpen Access
Characterization of an antibody scFv that recognizes fibrillar insulin and β-amyloid using atomic force microscopy
Nanomedicine Nanotechnology Biology and Medicine·2008· 24 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

Hing C. Wong(19), Peter R. Rhode(16), Emily K. Jeng(13), Kaiping Han(10), Xiaoyun Zhu(10), Bai Liu(9), Lin Kong(7), Wenxin Xu(7), Mark P. Rubinstein(7), Christopher B. Johnson(5), Ana C. Edwards(5), Sarah Alter(4), Wenxin Xu(4), Monica L. H. Jones(4), Lin Kong(4), Cheng Zhu(3), Bai Liu(3), Xiaoyue Chen(3), Michael R. Sierks(3), Jason L. Yovandich(2)